LMAT icon

LeMaitre Vascular

93.00 USD
+0.89
0.97%
At close Updated Sep 18, 3:18 PM EDT
1 day
0.97%
5 days
-0.64%
1 month
-2.15%
3 months
13.85%
6 months
9.53%
Year to date
1.67%
1 year
4.67%
5 years
182.16%
10 years
550.35%
 

About: LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

Employees: 664

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

17% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 98

0% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 28

0.04% less ownership

Funds ownership: 93.66% [Q1] → 93.62% (-0.04%) [Q2]

1% less capital invested

Capital invested by funds: $1.77B [Q1] → $1.76B (-$16.2M) [Q2]

2% less funds holding

Funds holding: 287 [Q1] → 282 (-5) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 4 [Q1] → 2 (-2) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$95
2% upside
Avg. target
$95
2% upside
High target
$95
2% upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Cantor Fitzgerald
Ross Osborn
$95
Neutral
Maintained
6 Aug 2025
Barrington Research
Michael Petusky
$95
Outperform
Upgraded
6 Aug 2025

Financial journalist opinion

Based on 3 articles about LMAT published over the past 30 days

Positive
Seeking Alpha
2 days ago
LeMaitre Vascular: Investment Debate Remains In Place
LeMaitre Vascular remains a long-term compounder, delivering strong Q2 results with 15% sales growth, robust margins, and increased dividends. LMAT's investment thesis is supported by pricing power, an expanding product pipeline, disciplined capital allocation, and consistent reinvestment driving high returns on capital. Valuation is fair-to-full at current levels, with a $110-$111 price target; compounding will come from intrinsic value growth rather than multiple expansion.
LeMaitre Vascular: Investment Debate Remains In Place
Neutral
GlobeNewsWire
20 days ago
LeMaitre to Participate at Upcoming Investor Conferences in September
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in four upcoming investor conferences.
LeMaitre to Participate at Upcoming Investor Conferences in September
Positive
Zacks Investment Research
22 days ago
Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think "Yes"
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think "Yes"
Positive
Zacks Investment Research
1 month ago
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
Positive
The Motley Fool
1 month ago
LeMaitre (LMAT) Q2 Revenue Jumps 15%
LeMaitre (LMAT) Q2 Revenue Jumps 15%
LeMaitre (LMAT) Q2 Revenue Jumps 15%
Neutral
Seeking Alpha
1 month ago
LeMaitre Vascular, Inc. (LMAT) Q2 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants David B. Roberts - President & Director Dorian LeBlanc - Chief Financial Officer George W.
LeMaitre Vascular, Inc. (LMAT) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
LeMaitre Vascular (LMAT) Beats Q2 Earnings and Revenue Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.52 per share a year ago.
LeMaitre Vascular (LMAT) Beats Q2 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
LeMaitre Q2 2025 Financial Results
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance.
LeMaitre Q2 2025 Financial Results
Positive
Zacks Investment Research
1 month ago
PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?
Neutral
GlobeNewsWire
2 months ago
LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025
BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025
Charts implemented using Lightweight Charts™